Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to Outperform at Mizuho

Amylyx Pharmaceuticals (NASDAQ:AMLX) was upgraded by investment analysts at Mizuho from a “neutral” rating to an “outperform” rating in a research report issued on Monday,Finviz reports. The brokerage presently has a $7.00 target price on the stock. Mizuho’s price objective would suggest a potential upside of 104.08% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $3.43 on Monday. The stock has a market capitalization of $303.90 million, a P/E ratio of -0.90 and a beta of -0.53. Amylyx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $7.27. The business has a 50-day moving average of $3.55 and a 200-day moving average of $4.07.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. Equities analysts expect that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insider Activity at Amylyx Pharmaceuticals

In related news, Director Bernhardt G. Zeiher acquired 10,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, March 20th. The stock was purchased at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $37,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at $11,108,327.09. The trade was a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,509 shares of company stock worth $222,586. Insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Blue Trust Inc. grew its position in shares of Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after purchasing an additional 4,883 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. Alpine Global Management LLC bought a new position in Amylyx Pharmaceuticals during the 4th quarter worth $45,000. RPO LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth $46,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $53,000. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.